Product Program year 2023 Source: CMS Open Payments

Xipere

Drug Ophthalmology

NDC 71565-040-01

Open in the dashboard

General payments

$891,976

3,428 payments

Research payments

0 payments

Through program year 2023, $891,976 in general payments and $0 in research payments were reported against Xipere (Ophthalmology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

3 rows

Year	Kind	Amount	Payments
2023	General	$251,553	1,424
2022	General	$561,963	1,882
2021	General	$78,460	122

Breakdown

Who paid General payments · program years 2021–2023

Bausch & Lomb Americas Inc. $813,510 3,305 payments
Bausch & Lomb, a division of Bausch Health US, LLC $78,460 122 payments
Salix Pharmaceuticals, a division of Bausch Health US, LLC $6 1 payment

Top recipients General payments · program year 2023

Steven Yeh Ophthalmology · Atlanta, GA $23,079 9% · 20 payments
Peter Chang Ophthalmology · Waltham, MA $18,483 7% · 19 payments
Vinay Shah Retina Specialist · Oklahoma City, OK $11,667 5% · 1 payment
Stephen Anesi Ophthalmology · Waltham, MA $11,158 4% · 9 payments
Rajiv Shah Ophthalmology · Winston Salem, NC $10,412 4% · 15 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2023.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2023

Ophthalmology $174,202 71% · 434 practitioners
Retina Specialist Ophthalmology $56,628 23% · 250 practitioners
Uveitis and Ocular Inflammatory Disease Ophthalmology $13,196 5% · 15 practitioners
Optometrist $1,214 <1% · 41 practitioners
Glaucoma Specialist Ophthalmology $368 <1% · 7 practitioners

The top 5 of 17 specialties; each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2023

Massachusetts $40,531 16% · 17 recipients
Texas $27,655 11% · 47 recipients
Georgia $23,936 10% · 20 recipients
California $20,982 8% · 108 recipients
Ohio $15,117 6% · 40 recipients

The top 5 of 41 states; each share is of general payments naming this product in 2023 where a state was reported.

The top 25 states, free in the app

Given in the clinic

Part B · billing code

Medicare Part B billing codes matched to XIPERE
Billing code	Providers	Services	Paid by Medicare
Injection, triamcinolone acetonide (xipere), 1 mg J3299	27	27,502	$1,039,981

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

Records

3,428 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.